Research Topics
| Peter E BuckleySummaryAffiliation: Medical College of Georgia Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Lack of insight in schizophrenia: impact on treatment adherencePeter F Buckley
Department of Psychiatry, Medical College of Georgia, 1515 Pope Avenue, Augusta, Georgia 30912, USA
CNS Drugs 21:129-41. 2007..The extent to which second-generation antipsychotic medications, including a recently released long-acting formulation, improve insight and/or enhance treatment adherence remains to be determined...
Neurotrophins and schizophreniaPeter F Buckley
Department of Psychiatry and Health Behavior, Medical College of Georgia, 1515 Pope Avenue, Augusta, Georgia 30912, United States
Schizophr Res 94:1-11. 2007..This article reviews the literature on neurotrophins and schizophrenia. A schema for understanding the neurobiology of relapse in schizophrenia is offered...
Strategies for dosing and switching antipsychotics for optimal clinical managementPeter F Buckley
Department of Psychiatry and Health Behavior, Medical College of Georgia, Augusta, GA 30912, USA
J Clin Psychiatry 69:4-17. 2008....
Clinicians' recognition of the metabolic adverse effects of antipsychotic medicationsPeter F Buckley
Department of Psychiatry and Health Behavior, Medical College of Georgia, 1515 Pope Avenue, Augusta, GA 30912 3800, USA
Schizophr Res 79:281-8. 2005..The extent of monitoring for metabolic adverse effects was low and inconsistent across measures and in frequency of evaluation. Ongoing efforts are needed to support and encourage change in clinician practice...
Treatment of agitation and aggression in bipolar mania: efficacy of quetiapinePeter F Buckley
Department of Psychiatry and Health Behavior, Medical College of Georgia, Augusta, Georgia 30912, USA
J Affect Disord 100:S33-43. 2007..Agitation and aggression are potentially disruptive and dangerous features of bipolar mania. This analysis evaluated the effects of quetiapine on agitation and aggression in patients with bipolar I mania...
Olanzapine: a critical review of recent literaturePeter F Buckley
Department of Psychiatry and Health Behavior, Medical College of Georgia, 1515 Pope Avenue, Augusta, GA 30912 3800, USA
Expert Opin Pharmacother 6:2077-89. 2005..New information continues to emerge on the impact of olanzapine on schizophrenia and on aspects of the course of mood disorders. There are also continued efforts to understand, predict and manage the side-effect risk with olanzapine...
Prevalence and consequences of the dual diagnosis of substance abuse and severe mental illnessPeter F Buckley
Department of Psychiatry and Health Behavior, Medical College of Georgia, Augusta, GA 30912, USA
J Clin Psychiatry 67:5-9. 2006....
First-episode schizophrenia. A window of opportunity for optimizing care and outcomesPeter E Buckley
Department of Psychiatry, Medical College of Georgia, Augusta 30912, USA
Postgrad Med . 2006....
Brain derived neurotropic factor in first-episode psychosisPeter F Buckley
Department of Psychiatry and Health Behavior, School of Medicine, Medical College of Georgia, Augusta, GA 30912, USA
Schizophr Res 91:1-5. 2007..Low BDNF levels at the onset of psychosis suggest that it may contribute to the pathogenesis of schizophrenia and/or perhaps could be a helpful neurobiological marker for possible early treatment intervention...
The history of the American Association of Chairs of Departments of PsychiatryPeter F Buckley
Medical College of Georgia, 1515 Pope Avenue, Augusta, GA 30912, USA
Acad Psychiatry 31:97-8. 2007
Introduction: the art and science of switching antipsychotic medicationsPeter F Buckley
Department of Psychiatry, Medical College of Georgia, Augusta, GA 30912, USA
J Clin Psychiatry 68:4. 2007
Receptor-binding profiles of antipsychotics: clinical strategies when switching between agentsPeter F Buckley
Department of Psychiatry, Medical College of Georgia, Augusta, GA 30912, USA
J Clin Psychiatry 68:5-9. 2007..An understanding of the differential receptor-binding profiles of the various antipsychotics can help clinicians anticipate and manage potential clinical issues that may be encountered when switching antipsychotic therapy...
Factors that influence treatment success in schizophreniaPeter F Buckley
Department of Psychiatry and Health Behavior, Medical College of Georgia, Augusta, GA 30912 3800, USA
J Clin Psychiatry 69:4-10. 2008..These factors can be conveniently grouped into 3 categories: treatment-related factors, patient-related factors, and environment- or system-related factors...
Leadership and professional workforce developmentPeter F Buckley
Department of Psychiatry and Health Behavior, Medical College of Georgia, Augusta, GA, USA
Psychiatr Clin North Am 31:105-22. 2008..This article chronicles the trajectory of workforce development and professional growth in psychiatry...
Second-generation antipsychotic medications in the treatment of mood disorders: focus on aripiprazolePeter F Buckley
Department of Psychiatry and Health Behavior, Medical College of Georgia, Augusta, Georgia 30912 3800, USA
Drugs Today (Barc) 41:5-11. 2005..There is also a pressing need for additional information on the long-term efficacy and safety of each second-generation antipsychotic agent during maintenance therapy for bipolar disorders...
A three-dimensional morphometric study of craniofacial shape in schizophreniaPeter F Buckley
Department of Psychiatry and Health Behavior, Medical College of Georgia, 1515 Pope Ave, Augusta, GA 30912 3800, USA
Am J Psychiatry 162:606-8. 2005..Advances in facial visualization now allow for three-dimensional anthropometric evaluations of potentially greater discriminatory power in examining the complex geometric relationships of facial topography...
When symptoms persist: clozapine augmentation strategiesP Buckley
Department of Psychiatry, Medical College of Georgia, Augusta 30912, USA
Schizophr Bull 27:615-28. 2001..Current systematic efforts to enhance the treatment of these patients with adjunctive therapies are worthy of being studied in carefully conducted clinical trials...
Treatment of the psychotic patient who is violentPeter F Buckley
Department of Psychiatry and Health Behavior, Medical College of Georgia, 1515 Pope Avenue, Augusta, GA 30912 3800, USA
Psychiatr Clin North Am 26:231-72. 2003..Violence risk reduction is not only crucial from a societal perspective, but also it is a humanitarian necessity to alleviate the burden and stigma for patients with serious mental illness...
Aripiprazole: efficacy and tolerability profile of a novel-acting atypical antipsychoticPeter F Buckley
Department of Psychiatry and Health Behavior, Medical College of Georgia, Augusta, GA 30912 3800, USA
Drugs Today (Barc) 39:145-51. 2003....
Maintenance treatment for schizophrenia with quetiapinePeter F Buckley
Department of Psychiatry and Health Behavior, Medical College of Georgia, Augusta, Georgia, USA
Hum Psychopharmacol 19:121-4. 2004..04 for BPRS and 2.43 for CGI severity of illness. Although limited by patient attrition, these OLE data suggest that an initial beneficial response with quetiapine treatment can be maintained over a long-term period...
Efficacy of quetiapine for the treatment of schizophrenia: a combined analysis of three placebo-controlled trialsPeter F Buckley
Department of Psychiatry and Health Behavior, Medical College of Georgia, Augusta, GA, USA
Curr Med Res Opin 20:1357-63. 2004..To determine the effectiveness of quetiapine (Seroquel) against specific aspects of schizophrenic symptomatology...
Effective dosing and dose equivalency of second-generation antipsychotic medicationsPeter F Buckley
Department of Psychiatry, Medical College of Georgia, Augusta, GA 30912, USA
CNS Spectr 9:24-31. 2004..There is a need for fixed-dose studies of each SGA. Additionally, dosing should be a primary consideration when designing and subsequently interpreting comparative studies between SGAs...
Insight and its relationship to violent behavior in patients with schizophreniaPeter F Buckley
Department of Psychiatry, Medical College of Georgia, 1515 Pope Ave, Augusta, GA 30912, USA
Am J Psychiatry 161:1712-4. 2004..Lack of insight affects the management of schizophrenia. The interrelationship between lack of insight and illness attributes in patients with schizophrenia who commit violent acts is important and underresearched...
Efficacy and tolerability of quetiapine in poorly responsive, chronic schizophreniaPeter F Buckley
Department of Psychiatry and Health Behavior Medical College of Georgia, 1515 Pope Avenue, Augusta, GA 30912, USA
Schizophr Res 66:143-50. 2004..Weight gain was modest but more apparent in quetiapine-treated patients. Quetiapine is an appropriate treatment choice in patients who do not respond to prior antipsychotic treatment...
The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 updateAlexander L Miller
Department of Psychiatry, The University of Texas Health Science Center at San Antonio, MC 7792, 7703 Floyd Curl Drive, San Antonio, TX 78229 3900, USA
J Clin Psychiatry 65:500-8. 2004..This article reports the recommendations developed in 2002 and 2003 by a group of experts, clinicians, and administrators...
The art and science of switching of antipsychotic medications, part 1Peter J Weiden
Department of Psychiatry, Schizophrenia Research Program, State University of New York Downstate Medical Center, Brooklyn, USA
J Clin Psychiatry 67:e15. 2006....
Metabolic profiles of second-generation antipsychotics in early psychosis: findings from the CAFE studyJayendra K Patel
Department of Psychiatry, University of Massachusetts Medical School, Worcester, MA 01605, USA
Schizophr Res 111:9-16. 2009..To further define the metabolic profiles of second-generation antipsychotics during the treatment of young patients with early psychosis, with a view to better inform prescribing clinicians...
The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 updateTroy A Moore
Department of Psychiatry, The University of Texas Health Science Center at San Antonio, USA
J Clin Psychiatry 68:1751-62. 2007....
Pharmacogenetics and schizophreniaAdriana Foster
Department of Psychiatry and Health Behavior, Medical College of Georgia, Augusta, GA 30912, USA
Psychiatr Clin North Am 30:417-35. 2007....
Clozapine-induced weight gain associated with the 5HT2C receptor -759C/T polymorphismDel D Miller
Department of Psychiatry, University of Iowa Carver College of Medicine, Iowa City, Iowa 52242 1000, USA
Am J Med Genet B Neuropsychiatr Genet 133:97-100. 2005..Subjects without the -759T variant allele were at a greater risk for weight gain from clozapine over 6-months compared to those with the -759T allele...
Head size and schizophreniaPeter F Buckley
Medical College of Georgia, Department of Psychiatry and Behavioral Health, 1515 Pope Avenue, Augusta, GA 30192 3800
Schizophr Res 55:99-104. 2002..Head size was found to be normal in schizophrenia. The relationship of brain size to head size is elaborated...
Recovery and systems transformation for schizophreniaScott A Peebles
Department of Psychiatry and Health Behavior, Medical College of Georgia, Augusta, GA 30912, USA
Psychiatr Clin North Am 30:567-83. 2007..This article reviews the growing literature regarding recovery, offers a conceptual framework for understanding recovery, and discusses a specific manner in which systems transformation has begun to occur...
Psychiatric comorbidities and schizophreniaPeter F Buckley
Schizophr Bull 35:383-402. 2009....
Naturalistic studies of second generation antipsychotics in the treatment of schizophreniaC Simon Sebastian
Department of Psychiatry, Medical College of Georgia, 1515 Pope Avenue, Augusta, GA 30912, USA
Curr Med Chem 11:329-42. 2004..This review provides an account of representative studies for each second generation antipsychotic, which illustrate the contributions of naturalistic studies to our understanding of the evolving pharmacotherapy of schizophrenia...
The relationship between symptomatic remission and neuropsychological improvement in schizophrenia patients switched to treatment with ziprasidonePeter F Buckley
Medical College of Georgia, United States
Schizophr Res 94:99-106. 2007....
Pharmacotherapy for treatment-refractory schizophreniaScott P Van Sant
Medical College of Georgia, Department of Psychiatry and Health Behavior, Augusta, GA 30912, USA
Expert Opin Pharmacother 12:411-34. 2011..EXPERT OPINION: although there have been many advances in pharmacotherapy for schizophrenia, more well-designed trials are required to establish true efficacy and safety of current prescribing trends in clinical practice...
Reflections on leadership as chair of a department of psychiatryPeter F Buckley
Department of Psychiatry and Health Behavior, Medical College of Georgia, 1515 Pope Avenue, Augusta, GA 30912, USA
Acad Psychiatry 30:309-14. 2006..The continued need to be a knowledgeable leader in the national trends of education, research, and clinical systems of care is a real challenge...
Understanding and treating "first-episode" schizophreniaPeter J Weiden
Department of Psychiatry, University of Illinois Medical Center, Chicago, IL, USA
Psychiatr Clin North Am 30:481-510. 2007..Clinicians and treatment services should try to identify "first-episode" patients in time to be able to anticipate and address these issues...
Reducing the burden of side effects during long-term antipsychotic therapy: the role of "switching" medicationsPeter J Weiden
Department of Psychiatry, State University of New York SUNY Downstate Medical Center, Brooklyn, NY, USA
J Clin Psychiatry 68:14-23. 2007..The authors explain how to evaluate the specific side effect in the context of the current medication and the overall management of the patient...
The art and science of switching antipsychotic medications, part 2Peter J Weiden
Department of Psychiatry, Schizophrenia Research Program, State University of New York Downstate Medical Center and Kings County Hospital Center, Brooklyn, USA
J Clin Psychiatry 68:e02. 2007....
Treating movement disorders and akathisia as side effects of antipsychotic pharmacotherapyPeter F Buckley
Department of Psychiatry, Medical College of Georgia, Augusta, Georgia, USA
J Clin Psychiatry 69:e14. 2008..Switching from a typical to an atypical antipsychotic or between atypical antipsychotics involves considering a variety of factors relating to the patient, illness, medication, and the patient's environment...
Prevalence and consequences of dual diagnosisPeter F Buckley
Department of Psychiatry, Medical College of Georgia, Augusta, USA
J Clin Psychiatry 67:e01. 2006..Screening, assessment, and integrated treatment plans for dual diagnosis to address both the substance use disorder and the mental illness are strongly recommended...
First-episode psychosis: a window of opportunity for best practicesPeter F Buckley
Department of Psychiatry and Health Behavior, Medical College of Georgia, Augusta, GA, USA
CNS Spectr 12:1-12; discussion 13-4; quiz 15-6. 2007..The use of first- or second-generation antipsychotics for psychosis treatment, dosing guidelines, and the antipsychotic side-effect profile will also be addressed...
Immersing practitioners in the recovery model: an educational program evaluationScott A Peebles
Charlie Norwood Veterans Administration Medical Center, Augusta, GA, USA
Community Ment Health J 45:239-45. 2009..Findings generally supported the effectiveness of the intervention in increasing providers' knowledge of recovery and a shift in recovery-supporting attitudes...
Optimizing treatment of schizophrenia. Enhancing affective/cognitive and depressive functioningDavid L Ginsberg
Georgetown University School of Medicine, USA
CNS Spectr 10:1-13; discussion 14-15. 2005..Additionally, relative to older medications, atypicals have demonstrated benefit in improving some of the cognitive impairments...
Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, fixed-dose studyBruce J Kinon
Eli Lilly and Company, Lilly Corporate Center, Drop Code 4133, Indianapolis, IN 46285, USA
J Clin Psychopharmacol 28:392-400. 2008....
Stimulus sequence affects schizophrenia-normal differences in event processing during an auditory oddball taskCasey S Gilmore
Department Psychology, University of Georgia, Psychology Building, Athens, GA 30602 3013, USA
Brain Res Cogn Brain Res 24:215-27. 2005..Thus, schizophrenia compromises the ability to properly use context to solve even simple cognitive problems...
Update on the treatment and management of schizophrenia and bipolar disorderPeter F Buckley
Mental Health Research Center, Eastern State Hospital, Lexington, KY, USA
CNS Spectr 13:1-10; quiz 11-2. 2008..Research examining the pharmacology of commonly used medications for the treatment of both disorders is also presented...
Dose response and atypical antipsychotics in schizophreniaBruce J Kinon
Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Drop Code 4133, Indianapolis, IN 46285, USA
CNS Drugs 18:597-616. 2004..Furthermore, the higher doses are not associated with a significantly increased incidence of adverse events.Further studies are clearly needed to fully characterise the dose-response relationships of atypical antipsychotics...
Pharmacotherapy of delusional disorders in the context of offending and the potential for compulsory treatmentDouglas A Smith
Northcoast Behavioral Healthcare, Northfield, OH, USA
Behav Sci Law 24:351-67. 2006..This article reviews the available literature that is specific to the treatment of delusional disorder. In addition, it focuses on specific forensic and medicolegal aspects of managing patients with delusional disorder...
Rate of stimulation affects schizophrenia-normal differences on the N1 auditory-evoked potentialCasey S Gilmore
Department of Psychology, University of Georgia, Athens, GA 30602-3013, USA
Neuroreport 15:2713-7. 2004..These results suggest steady-state stimuli, up to a point, provide the extra information needed for schizophrenia patients to more efficiently integrate auditory information...
Paradoxical reaction to fluoxetineMuhammad N Momen
Psychosomatics 44:259-60. 2003
Dosing equivalency of second-generation antipsychotic medicationsPeter F Buckley
J Clin Psychopharmacol 25:501-2; discussion 502-4. 2005
Research Grants
- Relapse Prevention: Long-Acting Atypical AntipsychoticsPeter Buckley; Fiscal Year: 2007..Even relatively modest delays in relapse and improvement of long term functioning potentially resulting from a long acting second-generation medication can translate into substantial public health benefits. ..
